Recruiting

Olive Leaf Extracts in the Control of Diabet

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: -Diabets

ClinicalTrials.gov IDNCT05605704

PhasePHASE2, PHASE3

Enrollment500

SponsorUniversity of Monastir

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetes Mellitus, Type 2

About this study

Interventions

Drug: Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
Drug: Placebo Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.

Primary outcomes

rate of continuous glycemic monitoring and Hemoglobin A1C (90 days)

Eligibility information

Inclusion Criteria: * Patients over 18 years of age with: * diabetes. Exclusion Criteria: * Exclusion criteria: None.

Study locations

Semir Nouira, Monastir, Monastir Tunisia 5000 Tunisia

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.